Topical cenegermin 0.002% for pediatric neurotrophic keratopathy
- 25 April 2022
- journal article
- research article
- Published by SAGE Publications in European Journal of Ophthalmology
- Vol. 32 (6) , 3420-3424
Abstract
Purpose: To evaluate the efficacy and safety of cenegermin 0.002% ophthalmic drops in the management of pediatric neurotrophic keratopathy (NK).Methods: Retrospective chart review of children under the age of 18 years diagnosed with NK at Boston Children's Hospital/Massachusetts Eye and Ear Infirmary and treated with topical cenegermin 0.002% ophthalmic solution between June 2018 and June 2021 was performed. Data collection included etiology of NK, age at time of initiation of topical cenegermin, laterality, ethnicity, gender, history of previous ocular therapy, pre- and post-therapy best corrected visual acuity, pre- and post-therapy cornea examination, any adverse events from topical cenegermin, associated ocular conditions, and history of ocular surgeries.Results: The current study includes four eyes of four pediatric patients with a mean age of 4.5 ± 2.0 years at the time of initiation of topical cenegermin therapy. The mean time from NK diagnosis until start of topical cenegermin drops was 5.2 ± 4.3 months and mean follow-up time was 15 ± 9.6 months. In all four patients, marked improvement in epitheliopathy was demonstrated after completion of therapy. Best corrected visual acuity was measurable in 3 eyes of 3 patients, and it improved from a mean of 0.07 ± 0.01 to a mean of 0.29 ± 0.26 ( P = 0.3). No adverse events related to cenegermin therapy were noted.Conclusion: Topical cenegermin was effective in improving corneal healing for pediatric NK.Keywords
This publication has 13 references indexed in Scilit:
- Pediatric Use of Recombinant Human Nerve Growth Factor 20 μg/mL Eye Drops (Cenegermin) for Bilateral Neurotrophic Keratopathy in Congenital Corneal AnesthesiaCornea, 2020
- Successful Treatment of a Pediatric Neurotrophic Keratopathy With CenegerminCornea, 2020
- A case report of pediatric neurotrophic keratopathy in pontine tegmental cap dysplasia treated with cenegermin eye dropsMedicine, 2020
- Topical Recombinant Human Nerve Growth Factor (Cenegermin) for Neurotrophic KeratopathyOphthalmology, 2020
- Update On Cenegermin Eye Drops In The Treatment Of Neurotrophic KeratitisClinical Ophthalmology, 2019
- Cenegermin in Pediatric Neurotrophic KeratopathyCornea, 2019
- Neurotrophic keratopathyProgress in Retinal and Eye Research, 2018
- Understanding the Pathogenesis of Neurotrophic Keratitis: The Role of Corneal NervesJournal of Cellular Physiology, 2016
- Etiologies, Quantitative Hypoesthesia, and Clinical Outcomes of Neurotrophic KeratopathyEye & Contact Lens: Science & Clinical Practice, 2015
- Structural and functional outcomes of anaesthetic cornea in childrenBritish Journal of Ophthalmology, 2014